838 related articles for article (PubMed ID: 22033040)
21. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.
Pauwels RA; Löfdahl CG; Postma DS; Tattersfield AE; O'Byrne P; Barnes PJ; Ullman A
N Engl J Med; 1997 Nov; 337(20):1405-11. PubMed ID: 9358137
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety and asthma control measures with a budesonide/formoterol pressurized metered-dose inhaler in African American asthmatic patients: a randomized controlled trial.
Brown RW; O'Brien CD; Martin UJ; Uryniak T; Lampl KL
J Allergy Clin Immunol; 2012 Aug; 130(2):362-7.e9. PubMed ID: 22541245
[TBL] [Abstract][Full Text] [Related]
23. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
Berger WE; Noonan MJ
J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
[TBL] [Abstract][Full Text] [Related]
24. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.
Corren J; Korenblat PE; Miller CJ; O'Brien CD; Mezzanotte WS
Clin Ther; 2007 May; 29(5):823-843. PubMed ID: 17697902
[TBL] [Abstract][Full Text] [Related]
25. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
26. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
FitzGerald JM; Boulet LP; Follows RM
Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
[TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients.
Peters SP; Prenner BM; Mezzanotte WS; Martin P; O'Brien CD
Allergy Asthma Proc; 2008; 29(5):499-516. PubMed ID: 18694544
[TBL] [Abstract][Full Text] [Related]
29. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
[TBL] [Abstract][Full Text] [Related]
30. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety.
Bodzenta-Lukaszyk A; Buhl R; Balint B; Lomax M; Spooner K; Dissanayake S
J Asthma; 2012 Dec; 49(10):1060-70. PubMed ID: 23102189
[TBL] [Abstract][Full Text] [Related]
31. Budesonide/formoterol pressurized metered-dose inhaler: in chronic obstructive pulmonary disease.
Lyseng-Williamson KA
Drugs; 2009 Jul; 69(11):1459-70. PubMed ID: 19634924
[TBL] [Abstract][Full Text] [Related]
32. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
Dusser D; Vicaut E; Lefrançois G;
Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
[TBL] [Abstract][Full Text] [Related]
33. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler.
Chervinsky P; Baker J; Bensch G; Parasuraman B; Boggs R; Martin P; O'Dowd L
Ann Allergy Asthma Immunol; 2008 Nov; 101(5):463-73. PubMed ID: 19055199
[TBL] [Abstract][Full Text] [Related]
34. Bronchodilator effect of single-dose formoterol administered by pressurized metered-dose inhaler in children with asthma aged 6 to <12 years receiving budesonide.
Berger WE; Gillen M; Eckerwall G; Uryniak T; Trudo FJ; Lampl KL
Allergy Asthma Proc; 2014; 35(2):134-40. PubMed ID: 24717790
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P
Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869
[TBL] [Abstract][Full Text] [Related]
36. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study.
Rabe KF; Atienza T; Magyar P; Larsson P; Jorup C; Lalloo UG
Lancet; 2006 Aug; 368(9537):744-53. PubMed ID: 16935685
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-<12 years).
Pearlman DS; Eckerwall G; McLaren J; Lamarca R; Puu M; Gilbert I; Jorup C; Sandin K; Lanz MJ
Ann Allergy Asthma Immunol; 2017 Apr; 118(4):489-499.e1. PubMed ID: 28256307
[TBL] [Abstract][Full Text] [Related]
38. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G
Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
[TBL] [Abstract][Full Text] [Related]
40. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
Bölükbas S; Eberlein M; Eckhoff J; Schirren J
Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
